Skip to content

AXON LAB

Active
Public limited companyfounded 201412 yrs activeJan Mommaertslaan 20A, 1831 Machelen (Brab.), BelgiumKBO/BCE: BE 0546.789.493
Summary

AXON LAB has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €694,802 and a net result of €5,086. Equity is growing by ~10.8% per year across the filed fiscal years. Its solvency ranks better than 27% of 9592 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Risk analysisWatch ReportCompare
AXON LABActiveChecked score 82/100
Risk analysis ReportCompare

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
1 site
Size
€3.3mtotal assets 2025
Staff
13.3 FTE
Equity
€694,802
Profit
€5,086
Turnover not published (abridged schema)
Financial health
82 Excellent Checked score 2025
Bankruptcy chance 12 m
0.5%
Structure
Parent
Axon Lab AG · 100%
Accounts 73 d early0 of 18 deeds read
Why 82- 1 change of registered office in 24 months- Size: 13.3 FTE, total assets €3.3m+ Figures for FY 2025 (filed 19-05-2026)+ Founded in 2014Show the evidence

Checked score

Score 2025
82 / 100
Excellent
Probability in this band: under 0.55%
Better than 45% of its sector peers (NACE 46, small)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Average
Solvency 46-18
equity 21.2% of total assets
Liquidity 48+4
short-term debt 25.3% · cash 6.1%
Profitability 69+30
return on assets 0.2%
Bankruptcy probability, 12 months
0.5% Very low
0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,373 companies)
Last 24 months 11-2024: < 0.1%lowest value 12-2024: 0.1%▲ +147% vs 11-2024 01-2025: 0.1%● 0.0% vs 12-2024 02-2025: 0.1%▼ -5.2% vs 01-2025 03-2025: 0.1%● 0.0% vs 02-2025 04-2025: 0.1%▲ +10.9% vs 03-2025 05-2025: 0.2%▲ +25.4% vs 04-2025 06-2025: 0.2%▲ +26.8% vs 05-2025 07-2025: 0.5%▲ +157% vs 06-2025 08-2025: 0.5%● 0.0% vs 07-2025 09-2025: 0.5%● 0.0% vs 08-2025 10-2025: 0.5%● 0.0% vs 09-2025 11-2025: 0.5%● 0.0% vs 10-2025 12-2025: 0.5%▼ -1.8% vs 11-2025 01-2026: 0.5%● 0.0% vs 12-2025 02-2026: 0.5%● 0.0% vs 01-2026 03-2026: 0.5%● 0.0% vs 02-2026 04-2026: 0.5%▲ +8.8% vs 03-2026 05-2026: 0.6%▲ +21.2% vs 04-2026highest value 06-2026: 0.5%▼ -30.0% vs 05-2026 07-2026: 0.5%● 0.0% vs 06-2026 08-2026: 0.5%● 0.0% vs 07-2026 09-2026: 0.5%● 0.0% vs 08-2026 10-2026: 0.5%● 0.0% vs 09-2026
  • Figures for FY 2025 (filed 19-05-2026) lowers the probability
  • 1 change of registered office in 24 months raises the probability
  • Size: 13.3 FTE, total assets €3.3m raises the probability for this profile
  • Founded in 2014 lowers the probability for this profile
Credit up to €55,000 at 30 days acceptable
Liquidity ample (current ratio 3.54 against 2.02 in 2024; short-term debt: 25.3% and cash: 6.1% of total assets), but 78.8% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 46, small). Better than this share of them on solvency 24%, liquidity 58%, profitability 58%, growth against the median 38%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Figures for FY 2025 (filed 19-05-2026)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
In the bankruptcy model this factor raises the probability.
Belgian State Gazette
raises risk · Size: 13.3 FTE, total assets €3.3m
In the bankruptcy model this factor raises the probability for this profile.
NBB · annual accounts
lowers risk · Founded in 2014
In the bankruptcy model this factor lowers the probability for this profile.
KBO
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-05-2026, 73 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
73 d early
2024
55 d early
2023
77 d early
2022
80 d early
2021
79 d early
2020
74 d early
2019
80 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 74 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 16 May (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
04-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · abbreviated…
  2. Annual accounts filedfiscal year 2024 · abbreviated…
  3. Annual accounts filedfiscal year 2023 · abbreviated…

Key points

  • Positive: Staff rose in 2025from 8 FTE to 13.3 FTE ▲ 66.3% View
  • Among the largest 5% on gross marginsector median €190,616 · 9,554 companies €2.1m View
  • Positive: Always filed on timeaccounts within the deadline every year 8 years View
  • Positive: 7 profitable years in a rowprofit 2025: €5,086 7 years View
  • Known shareholderslargest: Axon Lab AG 100% 100% View

By topic

Financials

Fiscal year
2025
Total assets
€3.3m
Profit
€5,086
Solvency
21.2%
Go to Financials

Timeline

Events
15
Since
2017
Next accounts
by 31-07-2027
  1. 19-05-2026Annual accounts filed
  2. 06-06-2025Annual accounts filed
  3. 15-05-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
21-02-2014
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure